ECOG-ACRIN Cancer Research Group

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

[ECOG-ACRIN Cancer Research Group @eaonc]

Congratulations to Dr. Bob Gray of @HarvardChanSPH @DanaFarber on his retirement as @eaonc Group Statistician! 🎉 We’re grateful for his many contributions to the #CancerResearch community. Wishing him all the best in this next chapter!

[ECOG-ACRIN Cancer Research Group @eaonc]

Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://t.co/NJBtg6CQfJ

[ECOG-ACRIN Cancer Research Group @eaonc]

@MoghaddamSeyed Thank you for joining us!

[Seyed Moghaddam @MoghaddamSeyed]

It was an honor to present at The Robert L. Comis, MD Translational Science Symposium on the role that inflammation plays in tumorigenesis with the aim to find targets for cancer prevention and interception. Thanks ECOG-ACRIN cancer research group for this incredible opportunity.

[Miami Hem/Onc Program Director @HemOncMiami]

Proud of our @SylvesterCancer trainees named Fall 2026 Edith Peterson Mitchell, MD Health Equity Travel Scholars at the @eaonc Meeting in Philadelphia! 🎉 Congrats to our hem-onc fellow @dan_morgen and rad-onc residents @belladreyfuss25 & @xlabissieremd.

#HemOnc #RadOnc #HealthEquity #ClinicalTrials

[Chinmay Jani @Jani_Chinmay]

Grateful to @eaonc for the opportunity to present our research and for selecting me among the Young Investigator Award recipients for an oral presentation at the Fall meeting!

🧬🫁 I shared our findings from 14,246 patients with NSCLC, highlighting how the genomic drivers and tumor immune landscape differ across age groups, with important implications for precision oncology.

Thankful to my mentor @GlopesMd @SylvesterCancer and all our collaborators for their continued support! @Latinamd @Labcorp @NarjustFlorezMD @DionysiosWatson @DesaiP_Oncdoc

[Dr. Robert @robt_heartdoc]

That is a serious group on that stage. Collaborative groups like ECOG-ACRIN are where practice-changing trials actually get done. I'd have loved to be in the room for this one. Kudos for pulling them together. #CancerResearch

[ECOG-ACRIN Cancer Research Group @eaonc]

@BenBleibergMD @ValsamoA @CharuAggarwalMD @valarlabs Thank you for joining us!

[Ben Bleiberg @BenBleibergMD]

Enjoyed the opportunity to present our work developing an AI-powered novel histopathologic biomarker in early-stage NSCLC at the @eaonc Data Science Committee meeting.

Thank you for the invitation @ValsamoA!

#LCSM #DigitalPathology #LungCancer
@CharuAggarwalMD @valarlabs

[KMittaloncMD @KMittalmd]

Fantastic fall 2026 @eaonc meeting! Great to connect with colleagues nationwide and brainstorm on concepts in development. Honored to take on a leadership role within the Kidney Cancer Subcommittee as Chair for community - helping broaden access to kidney cancer research.

[ECOG-ACRIN Cancer Research Group @eaonc]

@CathyEngMD @jordanberlin5 @VUMCDiscoveries @KristenCiombor @RajivAgarwalMD @CardinMD 👏👏👏

[Michael Lidsky, MD, FACS @michael_lidsky]

Congrats @jordanberlin5 , what an outstanding honor! We surgeons very much appreciate your guidance and the wisdom you share, often and always! @eaonc

[ECOG-ACRIN Cancer Research Group @eaonc]

Do you have newly diagnosed #MultipleMyeloma and are either ineligible for or willing to delay #StemCell transplantation? If so, you may be eligible to participate in #ClinicalTrial EAA181/EQUATE. More info here: https://t.co/Ny8oyGFFbQ #MMSM #NDMM cc: @MM_Hub, @theMMRF

[ECOG-ACRIN Cancer Research Group @eaonc]

.@MonikaJoshimd and @PGrivasMDPhD are leading #ClinicalTrial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced #UrothelialCancer. https://t.co/pAPr7iuYmR

[ECOG-ACRIN Cancer Research Group @eaonc]

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck (#HNSCC) that has come back after initial therapy. Learn more: https://t.co/0liEjdhnwI #HeadAndNeckCancer #HNCA

[MJ @MonikaJoshimd]

Really enjoyed the ECOG-ACRIN Fall Meeting! Great to catch up with colleagues, meet new collaborators, and talk through ideas for moving our trials forward. Thanks to everyone who helped put together such a worthwhile meeting!

[Vincent Rajkumar @VincentRK]

Very interesting and pertains to myeloma even more.

Dr. Mark Rocschewski @MSKCancerCenter presenting at @eaonc Heme Malignancy session showed this interesting slide pertaining to large cell lymphoma.

Patients who clear circulating tumor DNA of course do well. But what’s interesting is 25% of patients with detectable circulating tumor DNA have no recurrence. A real plateau!

Residual ctDNA (or MRD) may not necessarily mean bad outcome.

[ECOG-ACRIN Cancer Research Group @eaonc]

Do you have early-stage #melanoma and are age 75 or older? If so, you may be eligible to participate in this study of a potential new treatment approach. More info: https://t.co/w8gx60ULqd #SkinCancer #MelanomaResearch

[ECOG-ACRIN Cancer Research Group @eaonc]

ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer | EA2251 will be led by Deirdre Cohen @TischCancer and supported by @theNCI and @SMMT_TX

https://t.co/rPh7CUTDlg

[Petros Grivas @PGrivasMDPhD]

Respect to amazing legend in biostatistics Bob Gray who has transformed the field of biostatistics with huge impact in oncology globally! Wonderful to see #NancyDavidson @fredhutch @jsparano @AACRPres & others commenting on his career! Congrats on retirement!
@eaonc
@VincentRK